Cargando…

Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study

BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) manifest in the early stages of the disease and impair patients’ and caregivers’ quality of life. OBJECTIVE: To assess the effectiveness of the nutritional supplement Fortasyn Connect on BPSD for 12 months in people with mild cogni...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilar-Barberà, Miquel, Soler-Girabau, Paquita, Tabuenca-Martín, Ana Isabel, Prieto-del Val, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200227/
https://www.ncbi.nlm.nih.gov/pubmed/37066911
http://dx.doi.org/10.3233/JAD-221122
_version_ 1785045096432926720
author Aguilar-Barberà, Miquel
Soler-Girabau, Paquita
Tabuenca-Martín, Ana Isabel
Prieto-del Val, Laura
author_facet Aguilar-Barberà, Miquel
Soler-Girabau, Paquita
Tabuenca-Martín, Ana Isabel
Prieto-del Val, Laura
author_sort Aguilar-Barberà, Miquel
collection PubMed
description BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) manifest in the early stages of the disease and impair patients’ and caregivers’ quality of life. OBJECTIVE: To assess the effectiveness of the nutritional supplement Fortasyn Connect on BPSD for 12 months in people with mild cognitive impairment (MCI) and dementia in clinical practice. METHODS: Retrospective, national, single-center study of 236 patients (158 MCI and 78 dementia; 55.1% of AD etiology). BPSD were assessed with the Neuropsychiatric Inventory (NPI) at month 3, 6, and 12. Cognition (Mini-Mental State Examination, MMSE), depression (Geriatric Depression Scale, GDS), and everyday functioning (Blessed Dementia Scale, BLS-D; Rapid Disability Rating Scale 2, RDRS2) were also evaluated. RESULTS: Total NPI score, caregiver impact, and symptoms of depression, anxiety, apathy, and irritability improved after 3, 6, and 12 months from Fortasyn Connect initiation (p < 0.001). NPI decreases were more pronounced when baseline NPI score was higher than > 20 points (p < 0.001). The benefit was independent of gender, age, diagnosis, etiology, or concomitant treatment (p < 0.0001), although larger decreases in NPI total score were observed in MCI patients (p < 0.0001). After 12 months, GDS scores decreased (p = 0.042), and MMSE, BLS-D, and RDRS 2 scores remained stable. CONCLUSION: Fortasyn Connect improved BPSD over at least a year in patients with MCI and dementia. Depression, anxiety, apathy, and irritability were the symptoms that improved the most. The benefit was independent of patients’ characteristics and treatment but was greater if prescribed early and when baseline NPI scores were higher.
format Online
Article
Text
id pubmed-10200227
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-102002272023-05-22 Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study Aguilar-Barberà, Miquel Soler-Girabau, Paquita Tabuenca-Martín, Ana Isabel Prieto-del Val, Laura J Alzheimers Dis Research Article BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) manifest in the early stages of the disease and impair patients’ and caregivers’ quality of life. OBJECTIVE: To assess the effectiveness of the nutritional supplement Fortasyn Connect on BPSD for 12 months in people with mild cognitive impairment (MCI) and dementia in clinical practice. METHODS: Retrospective, national, single-center study of 236 patients (158 MCI and 78 dementia; 55.1% of AD etiology). BPSD were assessed with the Neuropsychiatric Inventory (NPI) at month 3, 6, and 12. Cognition (Mini-Mental State Examination, MMSE), depression (Geriatric Depression Scale, GDS), and everyday functioning (Blessed Dementia Scale, BLS-D; Rapid Disability Rating Scale 2, RDRS2) were also evaluated. RESULTS: Total NPI score, caregiver impact, and symptoms of depression, anxiety, apathy, and irritability improved after 3, 6, and 12 months from Fortasyn Connect initiation (p < 0.001). NPI decreases were more pronounced when baseline NPI score was higher than > 20 points (p < 0.001). The benefit was independent of gender, age, diagnosis, etiology, or concomitant treatment (p < 0.0001), although larger decreases in NPI total score were observed in MCI patients (p < 0.0001). After 12 months, GDS scores decreased (p = 0.042), and MMSE, BLS-D, and RDRS 2 scores remained stable. CONCLUSION: Fortasyn Connect improved BPSD over at least a year in patients with MCI and dementia. Depression, anxiety, apathy, and irritability were the symptoms that improved the most. The benefit was independent of patients’ characteristics and treatment but was greater if prescribed early and when baseline NPI scores were higher. IOS Press 2023-05-16 /pmc/articles/PMC10200227/ /pubmed/37066911 http://dx.doi.org/10.3233/JAD-221122 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) License (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Aguilar-Barberà, Miquel
Soler-Girabau, Paquita
Tabuenca-Martín, Ana Isabel
Prieto-del Val, Laura
Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study
title Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study
title_full Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study
title_fullStr Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study
title_full_unstemmed Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study
title_short Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study
title_sort fortasyn connect improves neuropsychiatric symptoms in patients with mild cognitive impairment and dementia: results from a retrospective real-world study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200227/
https://www.ncbi.nlm.nih.gov/pubmed/37066911
http://dx.doi.org/10.3233/JAD-221122
work_keys_str_mv AT aguilarbarberamiquel fortasynconnectimprovesneuropsychiatricsymptomsinpatientswithmildcognitiveimpairmentanddementiaresultsfromaretrospectiverealworldstudy
AT solergirabaupaquita fortasynconnectimprovesneuropsychiatricsymptomsinpatientswithmildcognitiveimpairmentanddementiaresultsfromaretrospectiverealworldstudy
AT tabuencamartinanaisabel fortasynconnectimprovesneuropsychiatricsymptomsinpatientswithmildcognitiveimpairmentanddementiaresultsfromaretrospectiverealworldstudy
AT prietodelvallaura fortasynconnectimprovesneuropsychiatricsymptomsinpatientswithmildcognitiveimpairmentanddementiaresultsfromaretrospectiverealworldstudy